- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04293523
48 kuukauden tutkimus Eloctan pitkän aikavälin tehokkuuden arvioimiseksi nivelten terveyteen (A-MORE)
48 kuukauden, usean keskuksen havainnointitutkimus Eloctan pitkän aikavälin tehokkuuden arvioimiseksi nivelten terveyteen
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.
Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.
The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Groningen, Alankomaat
- University Medical Center Groningen/UMCG
-
-
-
-
-
Barcelona, Espanja
- Sant Johan De Deu
-
Barcelona, Espanja
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Espanja
- Hospital Vall d'Hebron
-
Cruces, Espanja
- Hospital Universitario Cruces
-
Donostia / San Sebastian, Espanja
- Hospital Universitario Donostia
-
Murcia, Espanja
- Hospital Virgen de la Arrixaca
-
Málaga, Espanja
- Hospital Universitario Carlos Haya
-
Navarro, Espanja
- Complejo Hospitalario de Navarra
-
Oviedo, Espanja
- Hospital Universitario Central de Asturias (HUCA)
-
Palma de Mallorca, Espanja
- Hospital Universitario Son Espases
-
Seville, Espanja
- Hospital Universitario Virgen del Rocío
-
Vigo, Espanja
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Bari, Italia
- University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
-
Cesena, Italia
- AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
-
Genova, Italia
- Giannina Gaslini Institute
-
Milan, Italia
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Parma, Italia
- University Hospital of Parma, AOUP, Haemophilia Center
-
Rome, Italia
- Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
-
Torino, Italia
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
-
-
-
-
-
Thessaloniki, Kreikka
- Ippokrateio Hospital Thessaloniki (adult department)
-
Thessaloniki, Kreikka
- Ippokrateio Hospital Thessaloniki (pediatric department)
-
-
-
-
-
Muscat, Oman
- The Royal Hospital
-
-
-
-
-
Gothenburg, Ruotsi
- Hematologimottagning Sahlgrenska
-
Malmö, Ruotsi
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
-
-
-
-
-
Berlin, Saksa
- Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
-
Bonn, Saksa
- Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Frankfurt, Saksa
- Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
-
Frankfurt, Saksa
- Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
-
Hamburg, Saksa
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Hanover, Saksa
- Medizinische Hochschule Hannover
-
Hanover, Saksa
- Werlhof-Institut für Hämostaseologie GmbH
-
Heidelberg, Saksa
- SRH-Klinikum Heidelberg
-
Mörfelden-Walldorf, Saksa
- HZRM Hämöphilie Zentrum Rhein Main
-
München, Saksa
- Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
-
-
-
-
-
Riyadh, Saudi-Arabia
- Dr Suliman Al Habib Hospital Riyadh
-
Riyadh, Saudi-Arabia
- King Faisal Specialised Hospital, KFSH Riyadh, Children
-
Riyadh, Saudi-Arabia
- King Faisal Specialist Hospital KFSH, Adults
-
Riyadh, Saudi-Arabia
- Riyadh Military Hospital (P.S.M.C)
-
-
-
-
-
Ljubljana, Slovenia
- University Medical Centre Ljubljana Division of Paediatrics
-
-
-
-
-
Helsinki, Suomi
- Helsinki University Central Hospital, New Children Hospital
-
Turku, Suomi
- Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
-
-
-
-
-
Bern, Sveitsi
- Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
-
Lausanne, Sveitsi
- Service et Laboratoire central d'hématologie, Adults
-
Sankt Gallen, Sveitsi
- Zentrum für Labormedizin
-
Zurich, Sveitsi
- Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
-
-
-
-
-
Brno, Tšekki
- University Hospital Brno
-
Ostrava, Tšekki
- University Hospital Ostrava
-
Prague, Tšekki
- Dept. of Pediatric Haematology and Oncology, University Hospital Motol
-
-
-
-
-
Tallinn, Viro
- Lastehaigla, Tallinn (Tallinn Children´s Hospital)
-
Tallinn, Viro
- The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
-
-
-
-
-
Canterbury, Yhdistynyt kuningaskunta
- East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
-
London, Yhdistynyt kuningaskunta
- Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.
Kuvaus
Inclusion Criteria:
- Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
- Have a diagnosis of haemophilia A
- At enrolment on prophylactic treatment with Elocta, independent of participation in the study
Exclusion Criteria:
- Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
- Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Hemophilia A patients
All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice. |
Extended half-life factor VIII product
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Joint health: Target joint development
Aikaikkuna: 48 months
|
Number of target joints |
48 months
|
|
Joint health: Target joint resolution
Aikaikkuna: 48 months
|
Number of resolved target joints |
48 months
|
|
Joint health: Target joint recurrence
Aikaikkuna: 48 months
|
Number of recurring target joints |
48 months
|
|
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Aikaikkuna: 48 months
|
Number of joint bleeding events per year, for treated bleeds |
48 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Aikaikkuna: 48 months
|
The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome. |
48 months
|
|
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Aikaikkuna: 48 months
|
The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles. The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome. |
48 months
|
|
Joint and physical evaluation for elbows, knees and ankles.
Aikaikkuna: 48 months
|
The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome. |
48 months
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Aikaikkuna: 48 months
|
Number of bleeding events per year, for treated bleeds |
48 months
|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Aikaikkuna: 48 months
|
Number of bleeding events per year, for all bleeds |
48 months
|
|
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Aikaikkuna: 48 months
|
Percentage (%) of study population with zero (0) joint bleeds |
48 months
|
|
Effectiveness of Elocta: Work productivity and impairment
Aikaikkuna: 48 months
|
Assessed by WPAI-SHP questionnaire |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Aikaikkuna: 48 months
|
Assessed by Haemo-QoL/Haem-A-QoL questionnaire |
48 months
|
|
Effectiveness of Elocta: Physical activity level
Aikaikkuna: 48 months
|
Assessed by the Saltin-Grimby scale |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Aikaikkuna: 48 months
|
Assessed by EQ-5D-5L/EQ-5D-Y questionnaire |
48 months
|
|
Effectiveness of Elocta: Severity of joint health
Aikaikkuna: 48 months
|
Assessed by Patient Global Impression of Severity of Joint Health questionnaire |
48 months
|
|
Effectiveness of Elocta: FVIII plasma levels
Aikaikkuna: 48 months
|
Percentage (%) of FVIII plasma level |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Aikaikkuna: 48 months
|
Assessed by medication dose |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Aikaikkuna: 48 months
|
Assessed by total number of exposure days per medication |
48 months
|
|
Usage of Elocta: Annualised injection frequency per subject
Aikaikkuna: 48 months
|
Assessed by prescription |
48 months
|
|
Usage of Elocta: Annualised factor consumption per subject
Aikaikkuna: 48 months
|
Assessed by prescription [IU/kg] |
48 months
|
|
Usage of Elocta: Adherence
Aikaikkuna: 48 months
|
Investigator assessed (Percentage (%)) |
48 months
|
|
Exploratory Objective
Aikaikkuna: 48 months
|
Influence of different Elocta prophylaxis regimens on long term joint health |
48 months
|
|
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Aikaikkuna: 48 months
|
Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level |
48 months
|
|
Exploratory Objective: Explore adherence to prescribed treatment regimen
Aikaikkuna: 48 months
|
florio HAEMO captured treatment adherence scores |
48 months
|
|
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Aikaikkuna: 48 months
|
florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps) |
48 months
|
|
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Aikaikkuna: 48 months
|
florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels |
48 months
|
|
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Aikaikkuna: 48 months
|
florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Target joint development, resolution and recurrence |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Annualised joint bleeding rate (AJBR) for treated bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Ultrasound (HEAD-US) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Clinical joint scoring (HJHS) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Occurrence of zero (0) joint bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Quality of Life assessed by Haemo-QoL/Haem-A-QoL |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Aikaikkuna: 48 months
|
Physical activity level assessed by the Saltin-Grimby scale |
48 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Study Physician, Swedish Orphan Biovitrum
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Geneettiset sairaudet, synnynnäiset
- Hematologiset sairaudet
- Veren hyytymishäiriöt
- Hemorragiset häiriöt
- Veren hyytymishäiriöt, perinnölliset
- Koagulaatioproteiinien häiriöt
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Hemic- ja imusuutteet
- Hemofilia A
- faktori VIII-Fc-fuusioproteiini
Muut tutkimustunnusnumerot
- Sobi.Elocta-005
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .